Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis
Trial details
- Registry ID
- NCT07916480
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Roflumilast Cream 0.3% for Moderate to Severe Atopic DermatitisNCT07916480 | ARQT | Phase 3 | Recruiting | 2028-04-27Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |